Searchable abstracts of presentations at key conferences in endocrinology

ea0086p367 | Thyroid | SFEBES2022

L-T3 Prescribing & Deprescribing - Single Centre Experience

Day Katie , Swe Myint Khin , Neupane Sankalpa , Swords Frankie , Ahluwalia Rupa

Introduction: 90-95% of patients with primary hypothyroidism respond well to levothyroxine (L-T4) therapy. A minority remain symptomatic despite optimised L-T4 therapy. There is limited evidence supporting the role of liothyronine (L-T3) in this subgroup of patients. By looking at 3- and 6-month trials, we aim to review our practice of L-T4/l-T3 therapy.Method: We reviewed medical and pharmacy records of all patients receiving L-T4/l-T3 therapy from Janu...